Cantargia, a biopharma spin-out of Lund University, raises SEK 7m from Sunstone Capital and LU Bioscience to fight leukaemia.

Lund University spin-out Cantargia, which is development therapeutics to treat leukaemia, has raised SEK 7m ($1m).

Venture firm Sunstone Capital invested €500k ($638k) in the Sweden-based biopharmaceutical firm, and LU Bioscience (LUBio), a holding company partially owned (20%) by Lund University, made up the difference with a further SEK 3m. Following the investment, Sunstone and LUBio will own 8% and 5% of Cantargia respectively.

Remaining shares in the firm are owned by the company founders, life science firm Innovagen, and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?